Pfizer may buy Ratiopharm
NEW YORK It appears that Pfizer has changed its mind a second time about buying Ratiopharm.
According to published reports, Pfizer has renewed its offer for the German generic drug maker, for $4 billion. That pits the world’s largest drug maker against generic drug makers Teva Pharmaceutical Industries and Actavis.
Pfizer has been on a hunt for opportunities lately, most notably with its acquisition of Wyeth, as it faces patent expirations on such high-selling drugs as the cholesterol medication Lipitor (atorvastatin).